MedTrace Logo

The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC

NCT05778253 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-03-21

No results posted yet for this study

Summary

The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.

Conditions

  • Lung Squamous Cell Carcinoma

Interventions

DIAGNOSTIC_TEST

WES and ctDNA detection

WES and ctDNA detection

Sponsors & Collaborators

  • Shanghai OrigiMed Co., Ltd.

    collaborator UNKNOWN

  • Second Xiangya Hospital of Central South University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-23
Primary Completion
2028-09-23
Completion
2029-09-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05778253 on ClinicalTrials.gov